Eli Lilly CEO Dave Ricks details the company’s evolution into a global healthcare leader, driven by a 150-year commitment to scientific innovation and long-term strategic planning. The conversation centers on the company's dominant position in the cardiometabolic market, specifically the success of GLP-1 and GIP receptor agonists like Mounjaro and Zepbound. Ricks highlights the potential for these therapies to treat conditions beyond obesity, including inflammation and neurodegenerative diseases like Alzheimer’s. He also addresses the strategic shift toward direct-to-consumer distribution via Lilly Direct, which improves access and provides real-time consumer insights. Looking forward, the company prioritizes a "string of pearls" M&A strategy to fuel growth, aiming to maintain a competitive edge through rapid R&D cycles and a diversified pipeline that addresses significant unmet medical needs in brain health and oncology.
Sign in to continue reading, translating and more.
Open full episode in Podwise